Aamirah Mussa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aamirah Mussa has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Chelsea Morroni
Botswana Harvard Health Partnership, Princess Marina Hospital, Private Bag B0 320, Gaborone, Botswana
9 shared publicationsAdriane Wynn
Botswana Harvard Health Partnership, Princess Marina Hospital, Private Bag B0 320, Gaborone, Botswana
6 shared publicationsBame Bame
Botswana Harvard Health Partnership, Princess Marina Hospital, Private Bag B0 320, Gaborone, Botswana
5 shared publicationsChibuzor M Babalola
University of Southern California, Los Angeles, California, USA
4 shared publicationsJoseph Makhema
Botswana‐Harvard AIDS Institute Partnership Gaborone Botswana
4 shared publicationsRebecca Ryan
Botswana Harvard Health Partnership, Gaborone, Botswana
4 shared publications
Latest Publications
- Open Access
High diversity amongst African Treponema pallidum genomes provides a window into global transmission dynamics of syphilis: A genomic epidemiology study
Background: Global syphilis rates have risen dramatically since the early 2000s. Genomes can be used to inform rational control and intervention strategies by enhancing surveillance and ensuring vaccines have broad global utility. However, although >1000 Treponema pallidum genomes are now available from high-income countries, genomic data from Africa remain limited. Methods: We combined samples from 1198 participants recruited into a genital ulcer aetiology study in Botswana, Ghana, Uganda and Zimbabwe (collected 2022-2023) with 276 samples from national syphilis surveillance in South Africa to generate 147 novel African T. pallidum genomes (collected 2006-2023). Combining these with 167 publicly available African genomes and 1062 genomes from 24 non-African countries, we performed contextual population genomic analyses to understand the T. pallidum genomic diversity and transmission within and between African countries and the rest of the world. Findings: Contrasting with previous studies showing global circulation of highly similar T. pallidum , we found remarkable diversity amongst African T. pallidum . Of 56 sublineages, 20 were exclusively found amongst 6 African countries, 31 were found amongst 24 non-African countries, and 5 were found in both. Sublineage sharing between Africa and the rest of the world was rare, with 83.8% of African syphilis caused by locally circulating sublineages. Only 20.1% of African syphilis was resistant to macrolides (global average = 68.6%); where resistance occurred, this was strongly linked to introduction of global sublineages into Africa. Interpretation: African T. pallidum is characterised by locally circulating strains not found globally. Since sublineage sharing between countries is low, cataloguing African T. pallidum diversity will require intense local sampling in many countries. These findings will inform ongoing strategies for genomic surveillance and vaccine design, whilst contributing to our understanding of the spread of antimicrobial resistance in Africa, enabling refined treatment guidelines based on local data. Funding: Wellcome and the Gates Foundation.
Open AccessHigh diversity amongst African Treponema pallidum genomes provides a window into global transmission dynamics of syphilis: A genomic epidemiology study
Background: Global syphilis rates have risen dramatically since the early 2000s. Genomes can be used to inform rational control and intervention strategies by enhancing surveillance and ensuring vaccines have broad global utility. However, although >1000 Treponema pallidum genomes are now available from high-income countries, genomic data from Africa remain limited. Methods: We combined samples from 1198 participants recruited into a genital ulcer aetiology study in Botswana, Ghana, Uganda and Zimbabwe (collected 2022-2023) with 276 samples from national syphilis surveillance in South Africa to generate 147 novel African T. pallidum genomes (collected 2006-2023). Combining these with 167 publicly available African genomes and 1062 genomes from 24 non-African countries, we performed contextual population genomic analyses to understand the T. pallidum genomic diversity and transmission within and between African countries and the rest of the world. Findings: Contrasting with previous studies showing global circulation of highly similar T. pallidum , we found remarkable diversity amongst African T. pallidum . Of 56 sublineages, 20 were exclusively found amongst 6 African countries, 31 were found amongst 24 non-African countries, and 5 were found in both. Sublineage sharing between Africa and the rest of the world was rare, with 83.8% of African syphilis caused by locally circulating sublineages. Only 20.1% of African syphilis was resistant to macrolides (global average = 68.6%); where resistance occurred, this was strongly linked to introduction of global sublineages into Africa. Interpretation: African T. pallidum is characterised by locally circulating strains not found globally. Since sublineage sharing between countries is low, cataloguing African T. pallidum diversity will require intense local sampling in many countries. These findings will inform ongoing strategies for genomic surveillance and vaccine design, whilst contributing to our understanding of the spread of antimicrobial resistance in Africa, enabling refined treatment guidelines based on local data. Funding: Wellcome and the Gates Foundation.
- 23 October 2025
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (3) , 166-172
Is screening and treating asymptomatic chlamydia and gonorrhoea among pregnant women cost-effective to prevent preterm birth and low birth weight in Botswana?
Objectives: We investigated the costs and cost-effectiveness of screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae among asymptomatic pregnant women in Botswana to prevent preterm birth/low birth weight, compared with no microbiological screening. Methods: A health systems perspective and microcosting approach were used to estimate the costs of screening, treatment and partner treatment. Cost, epidemiological and effectiveness data were collected alongside the Maduo Study, a non-randomised cluster-controlled trial in Gaborone, Botswana evaluating the effect of C. trachomatis and N. gonorrhoeae screening on health outcomes among asymptomatic pregnant women and infants. We developed a decision tree to model a hypothetical cohort of 50 000 pregnant women receiving screening at first antenatal care and third trimester visits. We defined cost-effective as having an incremental cost per disability-adjusted life year (DALY) averted <$3625 (50% of Botswana’s 2023 gross domestic product per capita). Results: The cost per person screened was US$23.67. Additional costs of C. trachomatis and N. gonorrhoeae treatment were US$3.44 and US$4.60, respectively. The total cost of implementing the intervention among 50 000 pregnant women would be US$2 363 665. Compared with the standard-of-care, we projected an incremental cost per preterm birth/low birth weight outcome averted of US$962.56. Screening and treatment for C. trachomatis and N. gonorrhoeae were projected to be cost-effective with an incremental cost per DALY averted of US$580.51. However, the incremental cost-effectiveness ratio (ICER) was highly uncertain in sensitivity analyses, and assumptions about intervention effectiveness were highly influential on the ICER. Conclusions: Screening for C. trachomatis and N. gonorrhoeae infections has the potential to prevent serious adverse birth outcomes that contribute to childhood mortality, morbidity and high costs to the healthcare system. Additional research on the effectiveness of screening and treatment for these infections on preventing adverse birth outcomes is necessary to provide robust evidence that can inform cost-effectiveness analyses and decision-making.
- 23 October 2025
- Published by BMJ in Sexually Transmitted Infections
- Vol. 102 (3) , 166-172
Is screening and treating asymptomatic chlamydia and gonorrhoea among pregnant women cost-effective to prevent preterm birth and low birth weight in Botswana?
Objectives: We investigated the costs and cost-effectiveness of screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae among asymptomatic pregnant women in Botswana to prevent preterm birth/low birth weight, compared with no microbiological screening. Methods: A health systems perspective and microcosting approach were used to estimate the costs of screening, treatment and partner treatment. Cost, epidemiological and effectiveness data were collected alongside the Maduo Study, a non-randomised cluster-controlled trial in Gaborone, Botswana evaluating the effect of C. trachomatis and N. gonorrhoeae screening on health outcomes among asymptomatic pregnant women and infants. We developed a decision tree to model a hypothetical cohort of 50 000 pregnant women receiving screening at first antenatal care and third trimester visits. We defined cost-effective as having an incremental cost per disability-adjusted life year (DALY) averted <$3625 (50% of Botswana’s 2023 gross domestic product per capita). Results: The cost per person screened was US$23.67. Additional costs of C. trachomatis and N. gonorrhoeae treatment were US$3.44 and US$4.60, respectively. The total cost of implementing the intervention among 50 000 pregnant women would be US$2 363 665. Compared with the standard-of-care, we projected an incremental cost per preterm birth/low birth weight outcome averted of US$962.56. Screening and treatment for C. trachomatis and N. gonorrhoeae were projected to be cost-effective with an incremental cost per DALY averted of US$580.51. However, the incremental cost-effectiveness ratio (ICER) was highly uncertain in sensitivity analyses, and assumptions about intervention effectiveness were highly influential on the ICER. Conclusions: Screening for C. trachomatis and N. gonorrhoeae infections has the potential to prevent serious adverse birth outcomes that contribute to childhood mortality, morbidity and high costs to the healthcare system. Additional research on the effectiveness of screening and treatment for these infections on preventing adverse birth outcomes is necessary to provide robust evidence that can inform cost-effectiveness analyses and decision-making.
- 4 October 2024
- Published by BMJ in Sexually Transmitted Infections
- Vol. 101 (2) , 81-87
Effect of antenatalChlamydia trachomatisandNeisseria gonorrhoeaescreening on postdelivery prevalence and vertical transmission in Gaborone, Botswana: findings from an exploratory study
Objectives: Chlamydia trachomatisandNeisseria gonorrhoeaeare common sexually transmitted infections (STIs). Untreated infection in pregnancy can result in adverse neonatal outcomes, including vertical transmission. Screening for these infections is not routine in low- and middle-income countries (LMICs).Methods: The Maduo Study was a non-randomised cluster crossover trial in Botswana to provide preliminary data on the effect of antenatalC. trachomatisandN. gonorrhoeaescreening and treatment on postdelivery prevalence and vertical transmission to infants. Pregnant women asymptomatic for STIs were enrolled at four clinics (seven clusters). The intervention arm receivedC. trachomatisandN. gonorrhoeaescreening at first antenatal care, third trimester and postdelivery. The standard-of-care arm received postdelivery screening only. Infants of women with a positive test postdelivery in both arms were screened. A cluster-level analysis was performed to compare the risk of postdelivery infection between intervention and standard-of-care arms.Results: The study enrolled 500 women; 206 (82.1%) and 187 (75.1%) were retained in the intervention and standard-of-care arms, respectively and screened ≤12 weeks postdelivery.C. trachomatisprevalence in the intervention arm reduced from 22.7% at first antenatal care to 1.0% postdelivery.N. gonorrhoeaeprevalence reduced from 1.2% at first antenatal care to 0% postdelivery. The risk ofC. trachomatisand/orN. gonorrhoeaewas lower in the intervention arm postdelivery (0.6%) compared with the standard-of-care arm (15.7%); adjusted risk difference: −14.7% (95% CI −23.0%, −6.4%). Among 26 infants born to women with either infection postdelivery, 10 (38.5%) tested positive (C. trachomatis: 9;N. gonorrhoeae: 1).Conclusions: Postdelivery prevalence ofC. trachomatiswas significantly lower among pregnant women in Botswana who received diagnostic antenatal screening. Among women withC. trachomatisand/orN. gonorrhoeaepostdelivery, more than one-third transmitted the infection to their infants. This exploratory study suggests antenatal STI screening has the potential to reduce infection in newborns in similar LMIC settings.Trial registration number: NCT04955717.
- 4 October 2024
- Published by BMJ in Sexually Transmitted Infections
- Vol. 101 (2) , 81-87
Effect of antenatalChlamydia trachomatisandNeisseria gonorrhoeaescreening on postdelivery prevalence and vertical transmission in Gaborone, Botswana: findings from an exploratory study
Objectives: Chlamydia trachomatisandNeisseria gonorrhoeaeare common sexually transmitted infections (STIs). Untreated infection in pregnancy can result in adverse neonatal outcomes, including vertical transmission. Screening for these infections is not routine in low- and middle-income countries (LMICs).Methods: The Maduo Study was a non-randomised cluster crossover trial in Botswana to provide preliminary data on the effect of antenatalC. trachomatisandN. gonorrhoeaescreening and treatment on postdelivery prevalence and vertical transmission to infants. Pregnant women asymptomatic for STIs were enrolled at four clinics (seven clusters). The intervention arm receivedC. trachomatisandN. gonorrhoeaescreening at first antenatal care, third trimester and postdelivery. The standard-of-care arm received postdelivery screening only. Infants of women with a positive test postdelivery in both arms were screened. A cluster-level analysis was performed to compare the risk of postdelivery infection between intervention and standard-of-care arms.Results: The study enrolled 500 women; 206 (82.1%) and 187 (75.1%) were retained in the intervention and standard-of-care arms, respectively and screened ≤12 weeks postdelivery.C. trachomatisprevalence in the intervention arm reduced from 22.7% at first antenatal care to 1.0% postdelivery.N. gonorrhoeaeprevalence reduced from 1.2% at first antenatal care to 0% postdelivery. The risk ofC. trachomatisand/orN. gonorrhoeaewas lower in the intervention arm postdelivery (0.6%) compared with the standard-of-care arm (15.7%); adjusted risk difference: −14.7% (95% CI −23.0%, −6.4%). Among 26 infants born to women with either infection postdelivery, 10 (38.5%) tested positive (C. trachomatis: 9;N. gonorrhoeae: 1).Conclusions: Postdelivery prevalence ofC. trachomatiswas significantly lower among pregnant women in Botswana who received diagnostic antenatal screening. Among women withC. trachomatisand/orN. gonorrhoeaepostdelivery, more than one-third transmitted the infection to their infants. This exploratory study suggests antenatal STI screening has the potential to reduce infection in newborns in similar LMIC settings.Trial registration number: NCT04955717.
- Open Access
- 3 January 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 51 (3) , e1-e7
Syphilis Prevalence Among People Living With and Without HIV in Sub-Saharan Africa: A Systematic Review and Meta-Analysis
Background Syphilis is a curable sexually transmitted infection which, untreated, is associated with significant morbidity and mortality. In people living with HIV (PLWH), syphilis carries greater risks of disease progression. We estimated syphilis prevalence among PLWH in the general population in sub-Saharan Africa and compared prevalence among PLWH and without HIV. Methods We searched for studies published 1st January 2011 to 28th March 2022 reporting syphilis prevalence among PLWH in sub-Saharan Africa (PROSPERO#: CRD42020167328). We excluded studies in high-risk subpopulations. We estimated pooled syphilis prevalence among PLWH using random effects modelling and compared prevalence to people without HIV when included in the same study. We examined influences of region, study setting, and test type in subgroup analyses. Results We identified 926 studies; 53 were included in the meta-analysis. Pooled syphilis prevalence among PLWH was 7.3% (95% CI: 6.3-8.5%). Prevalence differed by region: 3.1% (95% CI: 2.2-4.0%) in Southern, 5.5% (95% CI: 2.3-9.3%) in West/Central, and 10.5% (95% CI: 8.0-13.1%) in Eastern Africa. Prevalence also differed by study setting: 13.8% (95% CI 5.7-23.0%) in SRH/STI care, 8.7% (95% CI 5.0-12.8%) in HIV care, 7.1% (95% CI 5.8-8.5%) in antenatal care and 3.8% (95% CI 2.0-5.8%) household/community-based settings. Syphilis prevalence was higher among PLWH than without HIV (RR: 3.5, 95% CI: 2.8-4.5). Conclusions Syphilis is highly prevalent among PLWH in sub-Saharan Africa and is more common among PLWH than without HIV. Integration of syphilis screening and management into HIV care may reduce complications of HIV-syphilis co-infection among PLWH in sub-Saharan Africa.
- 3 January 2024
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 51 (3) , e1-e7
Open AccessSyphilis Prevalence Among People Living With and Without HIV in Sub-Saharan Africa: A Systematic Review and Meta-Analysis
Background Syphilis is a curable sexually transmitted infection which, untreated, is associated with significant morbidity and mortality. In people living with HIV (PLWH), syphilis carries greater risks of disease progression. We estimated syphilis prevalence among PLWH in the general population in sub-Saharan Africa and compared prevalence among PLWH and without HIV. Methods We searched for studies published 1st January 2011 to 28th March 2022 reporting syphilis prevalence among PLWH in sub-Saharan Africa (PROSPERO#: CRD42020167328). We excluded studies in high-risk subpopulations. We estimated pooled syphilis prevalence among PLWH using random effects modelling and compared prevalence to people without HIV when included in the same study. We examined influences of region, study setting, and test type in subgroup analyses. Results We identified 926 studies; 53 were included in the meta-analysis. Pooled syphilis prevalence among PLWH was 7.3% (95% CI: 6.3-8.5%). Prevalence differed by region: 3.1% (95% CI: 2.2-4.0%) in Southern, 5.5% (95% CI: 2.3-9.3%) in West/Central, and 10.5% (95% CI: 8.0-13.1%) in Eastern Africa. Prevalence also differed by study setting: 13.8% (95% CI 5.7-23.0%) in SRH/STI care, 8.7% (95% CI 5.0-12.8%) in HIV care, 7.1% (95% CI 5.8-8.5%) in antenatal care and 3.8% (95% CI 2.0-5.8%) household/community-based settings. Syphilis prevalence was higher among PLWH than without HIV (RR: 3.5, 95% CI: 2.8-4.5). Conclusions Syphilis is highly prevalent among PLWH in sub-Saharan Africa and is more common among PLWH than without HIV. Integration of syphilis screening and management into HIV care may reduce complications of HIV-syphilis co-infection among PLWH in sub-Saharan Africa.
- 20 June 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (12) , 860-868
Case series and literature review of chlamydial ophthalmia neonatorum in Botswana
Background: We describe 12 cases of chlamydial ophthalmia neonatorum and the current scientific evidence on its prevention and treatment. The data presented were obtained from the “Maduo” study, a prospective observational study of the relationship between curable sexually transmitted infections and adverse neonatal outcomes at four antenatal clinics in Gaborone, Botswana. Methods: Infants of mothers with perinatal chlamydia infection were evaluated for chlamydial ophthalmia neonatorum based on clinical presentation of conjunctivitis or positive test via GeneXpert CT/NG assay. Data on 29 infants born to mothers with postnatal C. trachomatis infection were analysed. Results: 12 infants were diagnosed with chlamydial ophthalmia neonatorum. Eight of those cases were confirmed with the GeneXpert CT/NG assay while four were identified as probable cases based on clinical history and presentation. Overall, nine infants presented with signs of conjunctivitis, while three who had a positive diagnostic test result had asymptomatic infection. All but one infant had received ocular 1% tetracycline prophylaxis at birth, and four infants had signs suggestive of chlamydial pneumonia at presentation. Two out of five symptomatic cases whose mothers reported completion of their treatment course with erythromycin had lingering symptoms. Conclusions: Our findings affirm that the current prophylaxis and treatment modalities for chlamydial ophthalmia neonatorum are inadequate. To the extent feasible in low- and middle-income countries, we recommend implementation of routine C. trachomatis screening and treatment in pregnant women.
- 20 June 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (12) , 860-868
Case series and literature review of chlamydial ophthalmia neonatorum in Botswana
Background: We describe 12 cases of chlamydial ophthalmia neonatorum and the current scientific evidence on its prevention and treatment. The data presented were obtained from the “Maduo” study, a prospective observational study of the relationship between curable sexually transmitted infections and adverse neonatal outcomes at four antenatal clinics in Gaborone, Botswana. Methods: Infants of mothers with perinatal chlamydia infection were evaluated for chlamydial ophthalmia neonatorum based on clinical presentation of conjunctivitis or positive test via GeneXpert CT/NG assay. Data on 29 infants born to mothers with postnatal C. trachomatis infection were analysed. Results: 12 infants were diagnosed with chlamydial ophthalmia neonatorum. Eight of those cases were confirmed with the GeneXpert CT/NG assay while four were identified as probable cases based on clinical history and presentation. Overall, nine infants presented with signs of conjunctivitis, while three who had a positive diagnostic test result had asymptomatic infection. All but one infant had received ocular 1% tetracycline prophylaxis at birth, and four infants had signs suggestive of chlamydial pneumonia at presentation. Two out of five symptomatic cases whose mothers reported completion of their treatment course with erythromycin had lingering symptoms. Conclusions: Our findings affirm that the current prophylaxis and treatment modalities for chlamydial ophthalmia neonatorum are inadequate. To the extent feasible in low- and middle-income countries, we recommend implementation of routine C. trachomatis screening and treatment in pregnant women.
- 17 March 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (7) , 448-456
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection and associated factors among asymptomatic pregnant women in Botswana
Background: Chlamydia trachomatis ( C. trachomatis) and Neisseria gonorrhoeae ( N. gonorrhoeae) are curable sexually transmitted infections (STIs) that cause adverse pregnancy and neonatal outcomes. Most countries, including Botswana, do not offer C. trachomatis or N. gonorrhoeae screening during antenatal care (ANC) and instead use a syndromic approach for management of STIs. Methods: The Maduo Study is a prospective, cluster-controlled trial in Botswana evaluating the impact of diagnostic screening for antenatal C. trachomatis and N. gonorrhoeae infections to prevent adverse neonatal outcomes. Using baseline data from the Maduo Study (March 2021–March 2022), we determined the prevalence of C. trachomatis and N. gonorrhoeae infection among asymptomatic pregnant women in Botswana and correlates of infection using multivariable logistic regression. Results: Of 251 women who underwent C. trachomatis and N. gonorrhoeae screening at first ANC visit, 55 (21.9%, 95%CI 17.0–27.5) tested positive for C. trachomatis, 1 (0.4%, 95%CI 0–2.2) for N. gonorrhoeae; and 2 (0.8%, 95%CI 0–2.8) for dual C. trachomatis and N. gonorrhoeae infection. Older age was associated with lower odds (aOR 0.93; 95%CI 0.88–0.98; p = 0.011) while any alcohol use during pregnancy was associated with higher odds (aOR = 3.53; 95%CI 1.22–10.16; p = 0.020) of testing positive for C. trachomatis or N. gonorrhoeae. Conclusions: A high frequency of C. trachomatis infections was detected among asymptomatic pregnant women in Botswana indicating that many antenatal STIs are missed by the syndromic management approach. Our results highlight the need for diagnostic C. trachomatis screening during ANC in Botswana and other low- and middle-income countries that rely solely on the syndromic approach for management of STIs.
- 17 March 2023
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 34 (7) , 448-456
Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection and associated factors among asymptomatic pregnant women in Botswana
Background: Chlamydia trachomatis ( C. trachomatis) and Neisseria gonorrhoeae ( N. gonorrhoeae) are curable sexually transmitted infections (STIs) that cause adverse pregnancy and neonatal outcomes. Most countries, including Botswana, do not offer C. trachomatis or N. gonorrhoeae screening during antenatal care (ANC) and instead use a syndromic approach for management of STIs. Methods: The Maduo Study is a prospective, cluster-controlled trial in Botswana evaluating the impact of diagnostic screening for antenatal C. trachomatis and N. gonorrhoeae infections to prevent adverse neonatal outcomes. Using baseline data from the Maduo Study (March 2021–March 2022), we determined the prevalence of C. trachomatis and N. gonorrhoeae infection among asymptomatic pregnant women in Botswana and correlates of infection using multivariable logistic regression. Results: Of 251 women who underwent C. trachomatis and N. gonorrhoeae screening at first ANC visit, 55 (21.9%, 95%CI 17.0–27.5) tested positive for C. trachomatis, 1 (0.4%, 95%CI 0–2.2) for N. gonorrhoeae; and 2 (0.8%, 95%CI 0–2.8) for dual C. trachomatis and N. gonorrhoeae infection. Older age was associated with lower odds (aOR 0.93; 95%CI 0.88–0.98; p = 0.011) while any alcohol use during pregnancy was associated with higher odds (aOR = 3.53; 95%CI 1.22–10.16; p = 0.020) of testing positive for C. trachomatis or N. gonorrhoeae. Conclusions: A high frequency of C. trachomatis infections was detected among asymptomatic pregnant women in Botswana indicating that many antenatal STIs are missed by the syndromic management approach. Our results highlight the need for diagnostic C. trachomatis screening during ANC in Botswana and other low- and middle-income countries that rely solely on the syndromic approach for management of STIs.
- Open Access
- 24 January 2023
- Published by Wiley in Journal of the International AIDS Society
- Vol. 26 (1) , e26008
Incident HIV acquisition among pregnant women in Botswana: findings from the Tsepamo birth outcomes surveillance study
Introduction: In Botswana, where almost all pregnant women known to have HIV receive antiretroviral therapy, a large proportion of vertical HIV transmission may occur among women with incident undiagnosed HIV infection during pregnancy. Botswana guidelines recommend repeat HIV testing every 3 months in pregnancy, with at least one test in the third trimester. We evaluated the rate of repeat HIV testing, calculated HIV incidence during pregnancy and estimated missed seroconversions.Methods: In the Botswana Tsepamo Study, we abstracted HIV test dates and results from obstetric records of all women who delivered at maternity wards in 18 communities between 7th May 2017 and 20th August 2021. We defined seroconversion as an initial negative/indeterminate HIV test in pregnancy followed by a positive test during pregnancy/at delivery. The incidence rate (IR) of seroconversion was calculated among women with > = 2 known test dates. Missed seroconversions were estimated among women without a test in the third trimester by applying the IR to the time after the last HIV test until delivery.Results: Among 103,529 women delivering in the study period testing negative at the first test and with known conception and HIV test dates, 29,085 (28%) were tested in one trimester of pregnancy, 73,156 (71%) were tested in ≥ 2 trimesters of pregnancy and 9628 (9%) had a test in all trimesters. A total of 78,162 (75%) women had a third‐trimester test. There were 223 seroconversions (2.58/1000 pregnancies, 0.26%) among those with ≥ 2 known HIV test dates, yielding an IR of 0.69/100 person‐years. Among 25,289 women who did not have a test in the third trimester, we estimate approximately 58 seroconversions may have been missed during pregnancy due to a lack of repeat testing. Factors associated with seroconversion during pregnancy included younger age, less education and not being married.Conclusions: More than two‐thirds of women had repeat HIV testing in pregnancy and HIV incidence was low. However, an estimated 21% of seroconversions in pregnancy were likely missed due to a lack of re‐testing. To reach the goal of zero new paediatric HIV infections, Botswana will need to intensify repeat HIV testing in the third trimester of pregnancy.
- 24 January 2023
- Published by Wiley in Journal of the International AIDS Society
- Vol. 26 (1) , e26008
Open AccessIncident HIV acquisition among pregnant women in Botswana: findings from the Tsepamo birth outcomes surveillance study
Introduction: In Botswana, where almost all pregnant women known to have HIV receive antiretroviral therapy, a large proportion of vertical HIV transmission may occur among women with incident undiagnosed HIV infection during pregnancy. Botswana guidelines recommend repeat HIV testing every 3 months in pregnancy, with at least one test in the third trimester. We evaluated the rate of repeat HIV testing, calculated HIV incidence during pregnancy and estimated missed seroconversions.Methods: In the Botswana Tsepamo Study, we abstracted HIV test dates and results from obstetric records of all women who delivered at maternity wards in 18 communities between 7th May 2017 and 20th August 2021. We defined seroconversion as an initial negative/indeterminate HIV test in pregnancy followed by a positive test during pregnancy/at delivery. The incidence rate (IR) of seroconversion was calculated among women with > = 2 known test dates. Missed seroconversions were estimated among women without a test in the third trimester by applying the IR to the time after the last HIV test until delivery.Results: Among 103,529 women delivering in the study period testing negative at the first test and with known conception and HIV test dates, 29,085 (28%) were tested in one trimester of pregnancy, 73,156 (71%) were tested in ≥ 2 trimesters of pregnancy and 9628 (9%) had a test in all trimesters. A total of 78,162 (75%) women had a third‐trimester test. There were 223 seroconversions (2.58/1000 pregnancies, 0.26%) among those with ≥ 2 known HIV test dates, yielding an IR of 0.69/100 person‐years. Among 25,289 women who did not have a test in the third trimester, we estimate approximately 58 seroconversions may have been missed during pregnancy due to a lack of repeat testing. Factors associated with seroconversion during pregnancy included younger age, less education and not being married.Conclusions: More than two‐thirds of women had repeat HIV testing in pregnancy and HIV incidence was low. However, an estimated 21% of seroconversions in pregnancy were likely missed due to a lack of re‐testing. To reach the goal of zero new paediatric HIV infections, Botswana will need to intensify repeat HIV testing in the third trimester of pregnancy.
- 29 October 2022
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 50 (2) , 124-127
High Cure Rate Among Pregnant Women in a Chlamydia trachomatis and Neisseria gonorrhoeae Testing and Treatment Intervention Study in Gaborone, Botswana
A high cure rate was observed after testing and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae infection among pregnant women in a nonrandomized cluster trial in Gaborone, Botswana. Between March 2021 and March 2022, 251 pregnant women were tested for Chlamydia trachomatis and Neisseria gonorrhoeae infection in Botswana. Fifty-eight (23%) tested positive for at least 1 infection, and 57 (98%) were treated. No participants tested positive at test of cure. In some settings, cost of test of cure may outweigh the benefits.
- 29 October 2022
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 50 (2) , 124-127
High Cure Rate Among Pregnant Women in a Chlamydia trachomatis and Neisseria gonorrhoeae Testing and Treatment Intervention Study in Gaborone, Botswana
A high cure rate was observed after testing and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae infection among pregnant women in a nonrandomized cluster trial in Gaborone, Botswana. Between March 2021 and March 2022, 251 pregnant women were tested for Chlamydia trachomatis and Neisseria gonorrhoeae infection in Botswana. Fifty-eight (23%) tested positive for at least 1 infection, and 57 (98%) were treated. No participants tested positive at test of cure. In some settings, cost of test of cure may outweigh the benefits.
- Open Access
- 11 April 2022
- Published by Elsevier in Environmental Research
- Vol. 212 (Pt B) , 113252
Personal radiofrequency electromagnetic field exposure of adolescents in the Greater London area in the SCAMP cohort and the association with restrictions on permitted use of mobile communication technologies at school and at home
- 11 April 2022
- Published by Elsevier in Environmental Research
- Vol. 212 (Pt B) , 113252
Open AccessPersonal radiofrequency electromagnetic field exposure of adolescents in the Greater London area in the SCAMP cohort and the association with restrictions on permitted use of mobile communication technologies at school and at home